Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells

Documenti analoghi

• Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells
  di: Petros Patsali, et al.
  Pubblicazione: (2019-11-01)
• Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by <i>HBB^AS3</i> Gene Addition and Mutation-Specific RNA Interference
  di: Lola Koniali, et al.
  Pubblicazione: (2023-12-01)
• Context base editing for splice correction of IVSI-110 β-thalassemia
  di: Basma Naiisseh, et al.
  Pubblicazione: (2024-06-01)
• Functional correction and genome integrity with duplex base editing of β-thalassemic hematopoietic stem cells
  di: Nikoletta Y. Papaioannou, et al.
  Pubblicazione: (2026-02-01)
• Exploratory Review and In Silico Insights into circRNA and RNA-Binding Protein Roles in γ-Globin to β-Globin Switching
  di: Alawi Habara
  Pubblicazione: (2025-02-01)